Viropil™ is a licensed generic of Viread® + Dovato® (Dovato® is a combination of Tivicay® and Epivir®) produced in an FDA-approved factory in India. Viropil™ is a fixed-dose combination recommended by the WHO as a first-line complete treatment regimen for people living with HIV/AIDS.
- Viropil™ is a fixed-dose combination WHO-recommended first-line antiretroviral (ARV) complete regimen treatment option for people living with HIV/AIDS. The recommendation is based on Dolutegravir’s improved tolerability, higher antiretroviral efficacy, lower rates of treatment discontinuation, a higher genetic barrier to resistance, and fewer drug interactions than other ARV drugs. Additionally, both the U.S. Department of Health and Human Services and the European AIDS Clinical Society include Dolutegravir as a preferred medicine in their HIV/AIDS treatment guidelines.